Patents by Inventor Richard Cone
Richard Cone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897939Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.Type: GrantFiled: October 9, 2020Date of Patent: February 13, 2024Assignees: The University of North Carolina at Chapel Hill, The Johns Hopkins UniversityInventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
-
Publication number: 20230310311Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: ApplicationFiled: April 3, 2023Publication date: October 5, 2023Inventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Patent number: 11633350Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: GrantFiled: December 17, 2019Date of Patent: April 25, 2023Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Publication number: 20230074691Abstract: Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.Type: ApplicationFiled: August 29, 2022Publication date: March 9, 2023Inventors: Katharina Maisel, Laura Ensign, Justin Hanes, Richard Cone
-
Patent number: 11426345Abstract: Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CRC) under isotonic conditions. The hypo tonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectal at its CRC will form a “plug” of gel in the lumen.Type: GrantFiled: November 14, 2019Date of Patent: August 30, 2022Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Katharina Maisel, Laura Ensign, Justin Hanes, Richard Cone
-
Publication number: 20210061889Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.Type: ApplicationFiled: October 9, 2020Publication date: March 4, 2021Inventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
-
Patent number: 10829543Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.Type: GrantFiled: September 21, 2018Date of Patent: November 10, 2020Assignees: The University of North Carolina at Chapel Hill, The Johns Hopkins UniversityInventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
-
Patent number: 10668025Abstract: Mucus penetrating particles (MPPs) include one or more core polymers, one or more therapeutic, prophylactic and/or diagnostic agents; and one or more surface modifying agents. The surface modifying agents coat the surface of the particle in a sufficient density to enhance the diffusion of the modified nanoparticles throughout the mucosa, relative to equivalent nanoparticles that are not surface modified. Nanoparticles can be sufficiently densely coated with poly(ethylene glycol) (PEG) with a molecular weight of from 10 kD to 40 kD or greater coated with a surface density from about 0.1 to about 100 molecules/100 nm2, preferably from about 0.5 to about 50 molecules/100 nm2, more preferably from about 0.9 to about 45 molecules/100 nm2.Type: GrantFiled: October 31, 2016Date of Patent: June 2, 2020Assignee: The Johns Hopkins UniversityInventors: Justin Hanes, Katharina Maisel, Laura Ensign, Richard Cone
-
Patent number: 10646434Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: GrantFiled: September 6, 2018Date of Patent: May 12, 2020Assignee: The Johns Hopkins UniversityInventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Publication number: 20200138700Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: ApplicationFiled: December 17, 2019Publication date: May 7, 2020Inventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Publication number: 20200085733Abstract: Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.Type: ApplicationFiled: November 14, 2019Publication date: March 19, 2020Inventors: Katharina Maisel, Laura Ensign, Justin Hanes, Richard Cone
-
Patent number: 10485757Abstract: Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.Type: GrantFiled: January 26, 2016Date of Patent: November 26, 2019Assignee: The Johns Hopkins UniversityInventors: Katharina Maisel, Laura Ensign, Justin Hanes, Richard Cone
-
Patent number: 10398742Abstract: Methods and materials for treating bacterial vaginosis (“BV”) are provided. Cervicovaginal secretions (“CVS”) from a woman with Lactobacillus crispatus-dominated (>50%) vaginal microbiota is transplanted to women with BV as a method for restoring beneficial vaginal microbial communities and/or increasing resistance to sexually transmitted disease. Efficacy can be enhanced, or the properties of the endogenous CVS improved, through administration of an acidifying agent such as lactic acid. The examples demonstrate the role of healthy CVS in disease resistance, and the effect of pH on CVS properties. The examples also describe the collection and transplantation of healthy beneficial CVS into women at risk for, or after treatment for, BV.Type: GrantFiled: December 10, 2015Date of Patent: September 3, 2019Assignee: The Johns Hopkins UniversityInventors: Laura Ensign, Richard Cone, Justin Hanes
-
Publication number: 20190023769Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.Type: ApplicationFiled: September 21, 2018Publication date: January 24, 2019Inventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
-
Publication number: 20190000750Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: ApplicationFiled: September 6, 2018Publication date: January 3, 2019Inventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Patent number: 10100102Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating pathogen infection and providing contraception. In particular, the presently-disclosed subject matter relates to inhibiting and treating pathogen infection and providing contraception in a subject using compositions and antibodies capable of trapping pathogens or sperm in mucus, thereby inhibiting transport of pathogens or sperm across mucus secretions. The subject matter further relates to methods for monitoring the effectiveness of vaccines by detecting antibodies capable of trapping pathogens in mucus.Type: GrantFiled: October 29, 2013Date of Patent: October 16, 2018Assignees: The University of North Carolina at Chapel Hill, The Johns Hopkins UniversityInventors: Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kennetta Nunn, Durai Babu Subramani, Richard Cone
-
Patent number: 10092509Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbiocidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: GrantFiled: August 27, 2015Date of Patent: October 9, 2018Assignee: The Johns Hopkins UniversityInventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Publication number: 20180221293Abstract: Mucus penetrating particles (MPPs) include one or more core polymers, one or more therapeutic, prophylactic and/or diagnostic agents; and one or more surface modifying agents. The surface modifying agents coat the surface of the particle in a sufficient density to enhance the diffusion of the modified nanoparticles throughout the mucosa, relative to equivalent nanoparticles that are not surface modified. Nanoparticles can be sufficiently densely coated with poly(ethylene glycol) (PEG) with a molecular weight of from 10 kD to 40 kD or greater coated with a surface density from about 0.1 to about 100 molecules/100 nm2, preferably from about 0.5 to about 50 molecules/100 nm2, more preferably from about 0.9 to about 45 molecules/100 nm2.Type: ApplicationFiled: October 31, 2016Publication date: August 9, 2018Inventors: Justin Hanes, Katharina Maisel, Laura Ensign, Richard Cone
-
Publication number: 20180036354Abstract: Methods and materials for treating bacterial vaginosis (“BV”) are provided. Cervicovaginal secretions (“CVS”) from a woman with Lactobacillus crispatus-dominated (>50%) vaginal microbiota is transplanted to women with BV as a method for restoring beneficial vaginal microbial communities and/or increasing resistance to sexually transmitted disease. Efficacy can be enhanced, or the properties of the endogenous CVS improved, through administration of an acidifying agent such as lactic acid. The examples demonstrate the role of healthy CVS in disease resistance, and the effect of pH on CVS properties. The examples also describe the collection and transplantation of healthy beneficial CVS into women at risk for, or after treatment for, BV.Type: ApplicationFiled: December 10, 2015Publication date: February 8, 2018Inventors: Laura ENSIGN, Richard CONE, Justin HANES
-
Publication number: 20180021435Abstract: Hypotonic formulations of hydrogel forming polymers, preferably poloxamers, have been developed for enhanced delivery through mucosa of therapeutic, diagnostic, prophylactic or other agents, to epithelial tissues, especially those having a mucosal coating. The polymers are administered at a concentration above, at or less than their critical gelling concentration (CGC) under isotonic conditions. The hypotonicity of the formulation is adjusted so that the polymer gels at the lower concentration. A Poloxamer gel administered into the vagina or colorectum at its CGC will form a “plug” of gel in the lumen.Type: ApplicationFiled: January 26, 2016Publication date: January 25, 2018Inventors: Katharina Maisel, Laura Ensign, Justin Hanes, Richard Cones